Abstract:Background: Vancomycin pharmacokinetics are highly variable in patients with critical illnesses, and clinicians commonly use population pharmacokinetic (PPK) models based on a Bayesian approach to dose. However, these models are population-dependent, may only sometimes meet the needs of individual patients, and are only used by experienced clinicians as a reference for making treatment decisions. To assist real-world clinicians, we developed a deep learning-based decision-making system that predicts vancomycin therapeutic drug monitoring (TDM) levels in patients in intensive care unit. Objective: This study aimed to establish joint multilayer perceptron (JointMLP), a new deep-learning model for predicting vancomycin TDM levels, and compare its performance with the PPK models, extreme gradient boosting (XGBoost), and TabNet. Methods: We used a 977-case data set split into training and testing groups in a 9:1 ratio. We performed external validation of the model using 1429 cases from Kangwon National University Hospital and 2394 cases from the Medical Information Mart for Intensive Care-IV (MIMIC-IV). In addition, we performed 10-fold cross-validation on the internal training data set and calculated the 95% CIs using the metric. Finally, we evaluated the generalization ability of the JointMLP model using the MIMIC-IV data set. Results: Our JointMLP model outperformed other models in predicting vancomycin TDM levels in internal and external data sets. Compared to PPK, the JointMLP model improved predictive power by up to 31% (mean absolute error [MAE] 6.68 vs 5.11) on the internal data set and 81% (MAE 11.87 vs 6.56) on the external data set. In addition, the JointMLP model significantly outperforms XGBoost and TabNet, with a 13% (MAE 5.75 vs 5.11) and 14% (MAE 5.85 vs 5.11) improvement in predictive accuracy on the inner data set, respectively. On both the internal and external data sets, our JointMLP model performed well compared to XGBoost and TabNet, achieving prediction accuracy improvements of 34% and 14%, respectively. Additionally, our JointMLP model showed higher robustness to outlier data than the other models, as evidenced by its higher root mean squared error performance across all data sets. The mean errors and variances of the JointMLP model were close to zero and smaller than those of the PPK model in internal and external data sets. Conclusions: Our JointMLP approach can help optimize treatment outcomes in patients with critical illnesses in an intensive care unit setting, reducing side effects associated with suboptimal vancomycin administration. These include increased risk of bacterial resistance, extended hospital stays, and increased health care costs. In addition, the superior performance of our model compared to existing models highlights its potential to help real-world clinicians.

The Investigation and Prediction of Voriconazole-Associated Hepatotoxicity under Therapeutic Drug Monitoring

Voriconazole Therapeutic Drug Monitoring and Hepatotoxicity in Critically Ill Patients: A Nationwide Multicenter Retrospective Study

Development of a therapeutic drug‐monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study

Analysis of 84 Cases of Adverse Reactions Induced by Voriconazole

Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases

Predicting the Outcome of Voriconazole Individualized Medication Using Integrated Pharmacokinetic/Pharmacodynamic Model.

Therapeutic drug monitoring and safety of voriconazole in patients with liver dysfunction

Enhancing voriconazole therapy in liver dysfunction: exploring administration schemes and predictive factors for trough concentration and efficacy

Evaluation of voriconazole therapeutic drug monitoring in malignant hematology patients

Investigation of willingness in individualized medication of voriconazole in fungal infectious patients

Application of Machine Learning Classification to Improve the Performance of Vancomycin Therapeutic Drug Monitoring

A cohort study of vancomycin therapeutic drug monitoring

A Deep Learning-Based Approach for Prediction of Vancomycin Treatment Monitoring: Retrospective Study Among Patients With Critical Illness

The Effect of Voriconazole on Tacrolimus in Kidney Transplantation Recipients: A Real-World Study

Voriconazole plasma concentration monitoring in patients

Association between trough plasma voriconazole concentration and adverse drug reactions in elderly patients

Analysis of voriconazole trough plasma concentrations in critical patients

Individual Dose Recommendations for Drug Interaction Between Tacrolimus and Voriconazole in Adult Liver Transplant Recipients: A Semiphysiologically Based Population Pharmacokinetic Modeling Approach

A Machine Learning Model to Predict Risperidone Active Moiety Concentration Based on Initial Therapeutic Drug Monitoring

Comparison of LC-MS3 and LC-MRM Method for Quantifying Voriconazole and Its Application in Therapeutic Drug Monitoring of Human Plasma

Prediction of the Impact of CYP2C19 Polymorphism on Drug-Drug Interaction Between Voriconazole and Tacrolimus Using Physiologically- Based Pharmacokinetic Modelling